Ketamine One (NEO:MEDI.AQN) Capital Limited (LSE:CAPD) said its wholly-owned subsidiary, IRP Health Ltd recently opened two veteran-focused and multidisciplinary clinics in Comox Valley and Ottawa.
To date, the company said IRP has successfully performed over 10,000 unique treatments for past or present personnel of the Canadian Armed Forces and the Royal Canadian Mounted Police (RCMP), as well as first responders including firefighters, law enforcement officers, paramedics and emergency medical technicians.
The Comox Valley location is located at 780 30th Street in Courtenay, British Columbia, as the Comox Valley is one of the top retirement destinations in Canada for military veterans. The clinic is currently past the mid-way point of its inaugural program for RCMP personnel.
The Ottawa clinic is located at #305 1385 Bank Street, in an area that has a local population of over 9,000 veterans. The clinic’s practitioners have begun providing veterans with private, mental health-focused Occupational Therapy sessions. IRP continues to work toward establishing clinic locations in Halifax and Surrey, as also previously announced.
READ: Ketamine One says it intends to submit a draft registration statement for a proposed US IPO
Additionally, the company said the previously announced open-label study of patients with post-traumatic stress disorder (PTSD Study) who are undergoing IRP’s proprietary, 12-week physical therapy program, in affiliation with Ketamine One (NEO:MEDI.AQN)’s wholly-owned contract research organization KGK Science Inc, recently received ethics approval.
The next stage in preparation for the PTSD Study is to initiate a participant recruitment campaign and KGK expects to begin data collection early in 2022. A secondary benefit of the PTSD Study is that it will provide an opportunity for veterans who do not qualify for funding through Veterans Affairs Canada to participate in IRP’s beneficial program.
“I would like to commend Steven Inglefield and his team for getting IRP’s Comox Valley and Ottawa clinics to operational status and for beginning to treat veterans and first responders in multidisciplinary ways. Ketamine One continues to be a leader in mental health in Canada, and North America, thanks to the hard work of its employees,” said Adam Deffett, Interim CEO of Ketamine One in a statement.
“I am also excited about the advancement of the PTSD Study, which is a great example of two of our subsidiaries, IRP and KGK, working together with the goal of advancing the field mental health. As Canada’s only group of physical rehabilitation clinics exclusively treating members of the veteran and first responder population, IRP is filling a critical role in providing customized treatment programs for patients and is seeing strong demand for its services,” added Deffett.
Contact the author at jon.hopkins@proactiveinvestors.com